Clinically studied for knee comfort, mobility & joint function
A 12-week, prospective, randomised, double-blind, placebo-controlled human clinical study in 100 adults with mild-to-moderate knee osteoarthritis evaluated joint comfort, stiffness, mobility, daily physical function and inflammatory biomarkers.
Turmimax® BIO Knee OA Study
- Design
- Prospective, randomised, double-blind, placebo-controlled
- Participants
- N = 100 adults, 40–75 yrs, mild-to-moderate knee OA (KL Grade 2)
- Intervention
- Turmimax® BIO 200 mg/day vs placebo
- Duration
- 84 days (assessments at screening, Day 42, Day 84)
- Primary endpoints
- Total WOMAC, WOMAC pain, stiffness, physical function, VAS
- Secondary endpoints
- ESR, hs-CRP, IL-6, Leukotriene B4, MMP-3
- Safety
- Vitals, CBC, LFT, RFT, lipids, glucose, urinalysis, AEs
Results by Day 84
Clinical Efficacy Progress
Measures knee-joint pain during movement, walking, and resting.
Statistical significance p < 0.01 observed across all main sub-scores by Day 84.
Inflammatory & cartilage biomarkers
| Biomarker | Turmimax® BIO | Placebo |
|---|---|---|
| IL-6 | 5.84 → 4.75 ng/L | 5.95 → 6.78 ng/L |
| Leukotriene B4 | 653.79 → 587.52 ng/L | → 725.93 ng/L |
| MMP-3 | 64.98 → 55.96 ng/mL | 69.12 → 72.64 ng/mL |
| hs-CRP | 5650 → 5154 ng/mL | 5740 → 6087 ng/mL |
| ESR (Day 84) | 11.78 mm/h | 13.79 mm/h (p = 0.0108) |
Well tolerated across 84 days
No serious adverse events were reported in the supporting product document; the clinical presentation described only minimal side effects. Safety monitoring covered vitals, CBC, liver and renal function, lipids, fasting glucose and urinalysis.
Meaningful joint-health support
Turmimax® BIO at 200 mg/day supported clinically meaningful improvements in total WOMAC, pain, stiffness and the ability to perform daily activities, with favourable changes in IL-6, Leukotriene B4, MMP-3, hs-CRP and ESR.